OXB — Oxford BioMedica Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapMomentum Trap

Annual income statement for Oxford BioMedica, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	143	140	89.5	129	169
Cost of Revenue
Gross Profit	82.6	69.2	39.7	53	66
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	122	170	274	168	191
Operating Profit	20.8	-30.2	-184	-39.4	-22.5
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	19.9	-46	-189	-47.3	-31.9
Provision for Income Taxes
Net Income After Taxes	19	-45.2	-184	-48.6	-30.6
Minority Interest
Net Income Before Extraordinary Items
Net Income	19	-39.2	-157	-43.2	-30.1
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	19	-39.2	-157	-43.2	-30.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.222	-0.56	-0.97	-0.416	-0.327
Dividends per Share